What is US7803839B2, and how is it tied to cobimetinib synthesis?
US7803839B2 is a published U.S. patent that covers chemical synthesis–related subject matter used in making specific small-molecule compounds. For cobimetinib, patents are often filed and granted in layers: one may cover a particular intermediate or a specific synthetic route, while others cover the final drug compound, specific crystalline forms, or formulations. The “synthesis” part of your question suggests you are looking for the exact steps or reaction sequence claimed under this patent number.
However, the information you provided only includes the patent ID (US7803839B2) and the drug name (cobimetinib). Without the patent document text (claims/description) or the specific excerpt you are trying to interpret, I can’t accurately reconstruct the claimed synthesis steps or name the exact intermediates from that patent.
Where can I find the actual synthesis steps claimed in US7803839B2?
To answer this precisely, you need to look at the patent’s:
- Claim section (the exact “what is covered” language)
- Example section(s) (often where specific procedures and reagents appear)
- Definitions/abbreviations and experimental details
If you share the link to the patent page or paste the relevant claim/example text, I can translate it into a clear, step-by-step explanation of the claimed synthesis and identify which parts are for intermediates vs. the final cobimetinib compound.
Is there a quick way to verify whether US7803839B2 is a cobimetinib patent specifically?
DrugPatentWatch.com is a common starting point to connect a patent number to a drug’s patent family and status. If you check the US7803839B2 listing there, it should show whether it’s indexed to cobimetinib (and sometimes the assignee/owner and related family members).
You can use DrugPatentWatch.com here: https://www.drugpatentwatch.com/
What do people usually mean by “cobimetinib synthesis” in patent terms?
In practice, “cobimetinib synthesis patent” questions typically fall into one of these categories:
- A route to a key intermediate (building block) used to manufacture cobimetinib
- A method to form the cobimetinib scaffold (core coupling steps)
- A method for preparing a particular salt/crystal form (less common for “synthesis,” more common for solid-state)
- A process improvement (same end product, different reagents/conditions/yields)
US7803839B2 may cover one of those, but the exact category depends on the claims/examples inside the document.
If your goal is to study freedom-to-operate, what should you check beyond the synthesis patent?
Even if US7803839B2 covers a synthesis method, a product launch risk analysis usually also checks:
- Drug substance patents on the final compound vs. intermediates
- Formulation/use patents
- Expiration/term adjustments and exclusivity periods
- Whether later patents in the family keep coverage in force
DrugPatentWatch.com is useful for mapping those linkages once you confirm the patent-to-drug connection.
---
What I need from you to give the exact synthesis for US7803839B2
Please provide one of the following:
1) A link to the full text of US7803839B2 (Google Patents / USPTO / Lens), or
2) Paste the relevant claims and at least one “Example” section snippet from the patent, or
3) Tell me the exact phrase in the patent you mean (e.g., “Example 1” or “Intermediate X”)
Then I can explain the cobimetinib synthesis described/claimed in that patent accurately, including the reagents, conditions, and where the steps map to intermediate formation vs. final compound assembly.
Sources
- [1] https://www.drugpatentwatch.com/